Independent Research
NAMS Analysis
3 pieces of research on NewAmsterdam Pharma Company N.V.. We find the signal management buried in the earnings call.
3signal analyses
0news briefs
latest: Oct 14, 2026
Signal Analysis (3)
Analysis
NAMS CEO Buys As CSO Cashes Out Before PREVAIL Risk
NewAmsterdam Pharma's CEO made the only open-market insider purchase in three months while his Chief Scientific Officer sold $4.6 million in the same window — a…
Read analysis →Analysis
NAMS CSO Sold $3.4M Before Phase 3 Data Readout
NewAmsterdam Pharma's Chief Scientific Officer sold $3.4M worth of shares on August 24, immediately before the company's Phase 3 Obicetrapib data readout at ESC…
Read analysis →Analysis
NewAmsterdam Pharma: CAO Sold $6.7M, Stock Below Floor.
NewAmsterdam Pharma's CAO sold $6.71 million in shares across three months at prices between $29.96 and $35.69, and the stock now trades at $27.79, below her lo…
Read analysis →